MCRB Seres Therapeutics

Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management will participate in two upcoming investor conferences:

  • Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT.
  • UBS Global Healthcare Conference on Monday, May 22, 2017 in New York, NY; presentation at 1:30 p.m. EDT.

Live audio webcast of the presentations will be available under the “Investors and Media” section of Seres’ website. A replay of the presentations will become available after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres’ program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres’ clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

EN
01/05/2017

Underlying

MCRBSeres Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seres Therapeutics

 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Reports Second Quarter 2025 Financial Results and P...

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live bioth...

August 6, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Announce Second Quarter 2025 Financial Results a...

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join ...

July 22, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics Announces Leadership Transition Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasd...

July 22, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Dat...

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at th...

May 27, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% rel...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch